New treatment for T-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new approach to treat T-cell cancers (leukemia and lymphoma). It may be an option for adults with these cancers who are otherwise in reasonably good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of T-cell cancer (leukemia or lymphoma), which affects certain immune cells called T-cells.
- You are 18 years old or older.
- You are willing to sign a consent form to participate in the study.
- You do not have any serious health problems or active infections that would make it hard to follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial compares two types of stem cell transplants for adults with T-cell lymphoblastic lymphoma that has spread (stage III or IV) and has gone into remission after 3 rounds of chemo. The goal is to see which transplant approach works better.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
Hear when a new T-Cell Leukemia/Lymphoma, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.